Research Analysts Offer Predictions for Exelixis Q2 Earnings

Exelixis, Inc. (NASDAQ:EXEL) – Stock analysts at Zacks Research lifted their Q2 2026 EPS estimates for Exelixis in a note issued to investors on Monday, May 25th. Zacks Research analyst Team now forecasts that the biotechnology company will earn $0.75 per share for the quarter, up from their prior estimate of $0.72. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Exelixis’ current full-year earnings is $3.15 per share.

A number of other brokerages have also recently weighed in on EXEL. Truist Financial upgraded shares of Exelixis to a “strong-buy” rating in a report on Monday, April 27th. Barclays upped their price objective on shares of Exelixis from $44.00 to $45.00 and gave the stock an “equal weight” rating in a report on Monday, April 20th. Morgan Stanley upped their price objective on shares of Exelixis from $49.00 to $50.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 6th. Royal Bank Of Canada cut their price objective on shares of Exelixis from $46.00 to $43.00 and set a “sector perform” rating on the stock in a report on Monday, March 2nd. Finally, Wall Street Zen upgraded shares of Exelixis from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $47.35.

Exelixis Stock Performance

Shares of EXEL opened at $50.03 on Thursday. The stock has a market cap of $12.58 billion, a PE ratio of 16.62, a price-to-earnings-growth ratio of 1.06 and a beta of 0.38. Exelixis has a fifty-two week low of $33.76 and a fifty-two week high of $51.63. The firm’s 50-day simple moving average is $45.64 and its two-hundred day simple moving average is $44.10.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.75 by $0.12. The business had revenue of $610.81 million for the quarter, compared to analysts’ expectations of $607.51 million. Exelixis had a net margin of 35.08% and a return on equity of 39.89%. The business’s revenue was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.55 earnings per share.

Insider Buying and Selling

In related news, EVP Patrick J. Haley sold 32,110 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $49.81, for a total value of $1,599,399.10. Following the sale, the executive vice president owned 357,638 shares in the company, valued at approximately $17,813,948.78. This trade represents a 8.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Maria C. Freire sold 20,634 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $46.00, for a total transaction of $949,164.00. Following the completion of the sale, the director owned 100,819 shares in the company, valued at $4,637,674. This represents a 16.99% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 161,982 shares of company stock valued at $7,742,501 in the last ninety days. Corporate insiders own 2.60% of the company’s stock.

Institutional Investors Weigh In On Exelixis

Several institutional investors and hedge funds have recently added to or reduced their stakes in EXEL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Exelixis by 81.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,181 shares of the biotechnology company’s stock worth $1,592,000 after purchasing an additional 19,407 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Exelixis by 4.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,466,779 shares of the biotechnology company’s stock worth $54,153,000 after purchasing an additional 68,133 shares during the last quarter. Focus Partners Wealth boosted its holdings in Exelixis by 83.4% in the first quarter. Focus Partners Wealth now owns 38,458 shares of the biotechnology company’s stock worth $1,420,000 after purchasing an additional 17,483 shares during the last quarter. Geneos Wealth Management Inc. boosted its holdings in Exelixis by 134.3% in the first quarter. Geneos Wealth Management Inc. now owns 1,647 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 944 shares during the last quarter. Finally, Sivia Capital Partners LLC boosted its holdings in Exelixis by 23.8% in the second quarter. Sivia Capital Partners LLC now owns 14,362 shares of the biotechnology company’s stock worth $633,000 after purchasing an additional 2,764 shares during the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.